CING Latest Press Releases

-- November 13, 2025 --

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- November 10, 2025 --

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 Globe Newswire 8:00 AM

-- October 28, 2025 --

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control Globe Newswire 8:00 AM

-- October 23, 2025 --

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting Globe Newswire 4:45 PM

-- October 14, 2025 --

FDA Accepts Cingulate's New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date Globe Newswire 8:00 AM

-- September 17, 2025 --

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment Globe Newswire 8:45 AM

-- August 19, 2025 --

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Globe Newswire 8:45 AM

-- August 6, 2025 --

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 Globe Newswire 8:45 AM

-- July 29, 2025 --

Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software